Drugs for Immunotherapy Market Report 2025

This Drugs for Immunotherapy market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The drugs for immunotherapy market size has grown rapidly in recent years. It will grow from $255.14 billion in 2024 to $281.43 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to the rising incidence of cancer, unmet medical needs, cancer immunotherapy awareness, higher adoption rates of immunotherapeutic approaches, and rising investment by pharmaceutical giants.

The drugs for immunotherapy market size is expected to see rapid growth in the next few years. It will grow to $445.12 billion in 2029 at a compound annual growth rate (CAGR) of 12.1%. The growth in the forecast period can be attributed to combination therapies, personalized medicine, global expansion, biomarker-driven therapies, and increasing clinical trials. Major trends in the forecast period include advancements in immunology, advancements in car-t cell therapies, targeted immunotherapies, immunotherapy combinations, and neoantigen vaccines.

The burgeoning prevalence of cancer worldwide stands as the primary impetus behind the escalating demand for drugs in the immunotherapy market. The proliferation of cancer cases, attributed to factors like obesity, smoking, alcohol consumption, and dietary habits, is projected to soar significantly. Reports from Macmillan Cancer Support in October 2022 estimated a steep rise in cancer cases, predicting 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. With breast, lung, colon, rectum, and prostate cancers ranking as the most widespread types, lifestyle elements such as tobacco use, high BMI, limited fruit and vegetable intake, alcohol consumption, and lack of exercise contribute to roughly one-third of cancer-related deaths. This escalation in cancer incidence is set to drive up the demand for immunotherapy drugs, consequently fueling market growth.

The rising healthcare expenditure is expected to drive the growth of the immunotherapy drugs market in the future. Healthcare expenditure encompasses the total amount spent on healthcare goods and services within a specific region or country over a defined period. This includes expenses for doctor visits, hospital stays, surgeries, diagnostic tests, and treatments. Financial resources allocated for healthcare come from individuals, healthcare providers, insurance companies, and government agencies to cover costs related to immunotherapy drugs and treatments. For instance, a report from the Centers for Medicare & Medicaid Services in December 2022 indicated that U.S. healthcare spending increased by 4.1% to reach $4.5 trillion in 2022, surpassing the 3.2% growth seen in 2021. As a result, the rise in healthcare expenditure is driving the growth of the drugs for immunotherapy market.

Prominent entities within the immunotherapy drugs market are strategically focused on innovating novel products such as Keytruda (pembrolizumab), aimed at delivering dependable services to consumers. Keytruda, an immune checkpoint inhibitor categorized under immunotherapy, was launched by Merck & Co., Inc. in January 2023. Approved by the US Food and Drug Administration, this breakthrough therapy assists the immune system in combating cancer cells, notably approved as an adjuvant treatment for non-small cell lung cancer (NSCLC). This development stands as a substantial leap in cancer treatment, poised to positively impact the healthcare industry's landscape.

Manufacturers of drugs for immunotherapy market are increasingly collaborating or partnering with other companies to share technology, resources, and product knowledge and expand the business. For example, Illumina Inc. and Bristol-Myers Squibb (BMS) collaborated to utilize Illumina’s next-generation sequencing (NGS) technology to develop and commercialize in-vitro diagnostic (IVD) assays in support of Bristol-Myers Squibb's oncology portfolio. Allogene Therapeutics Inc. and Pfizer Inc. entered into an asset contribution agreement to use Pfizer’s portfolio of assets related to allogeneic CAR-T therapy.

In December 2024, Pfizer Inc., a pharmaceutical company based in the United States, completed the acquisition of Seagen for $43 billion. This acquisition is intended to enhance Pfizer's oncology portfolio by incorporating advanced immunotherapy treatments that utilize Seagen's innovative antibody-drug conjugates (ADCs) for targeted cancer therapy. Seagen Inc. is a biotechnology firm located in the U.S. that focuses on the production of antibody-drug conjugates (ADCs).

Immunotherapy drugs constitute a category of medications designed to modulate the immune system, either by enhancing or suppressing it, to bolster the body's defense against cancer, infections, and various ailments. This approach to cancer treatment harnesses the body's immune response to combat the disease.

The primary classes of immunotherapy drugs encompass monoclonal antibodies, interferons, interleukins, vaccines, checkpoint inhibitors, and other specialized treatments. Monoclonal antibodies, for instance, are produced by replicating a single white blood cell, allowing the lineage of each antibody to be traced back to its originating parent cell. These drugs find application across diverse medical domains such as cancer treatment, autoimmune conditions, inflammatory diseases, and combating infections. They are employed across various healthcare settings including hospitals, clinics, ambulatory surgical centers, and other healthcare facilities.

The drugs for immunotherapy market research report is one of a series of new reports that provides drugs for immunotherapy market statistics, including drugs for immunotherapy industry global market size, regional shares, competitors with drugs for immunotherapy market share, detailed drugs for immunotherapy market segments, market trends and opportunities, and any further data you may need to thrive in the drugs for immunotherapy industry. This drug for immunotherapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Major companies operating in the drugs for immunotherapy market include F. Hoffmann-La Roche Ltd., Novartis AG, Amgen Inc., AbbVie Inc., Merck & Co. Inc., GlaxoSmithKline plc, Eli Lilly and Company, Bristol-Myers Squibb, AstraZeneca plc, Johnson & Johnson, UbiVac, Pfizer Inc., Sanofi SA, Bayer AG, Celgene Corporation, Incyte Corporation, Juno Therapeutics Inc., Bluebird bio, Celldex Therapeutics, BeiGene, BioNTech AG, CytomX Therapeutics, Eisai Co. Ltd., Flexus Biosciences Inc., Genscript Biotech Corporation, Gilead Sciences Inc., Harpoon Therapeutics Inc., Heptares Therapeutics Ltd., Ignyta Inc., Immatics Biotechnologies, Jounce Therapeutics Inc.

North America was the largest region in the immunotherapy market in 2024. Middle East is expected to be the fastest growing region in the drug for immunotherapy market report during the forecast period. The regions covered in the drugs for immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the drugs for immunotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The drugs for immunotherapy market consist of sales of cytokines, CAR T-cell therapy, and cancer treatment vaccines. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.